Story

Keymed Biosciences Reports Positive Phase II Results for Sinusitis Drug CM512

ENTHMSVIIDZHZH-TWJAKOHI
Aug 10, 20262 min read
Keymed Biosciences Reports Positive Phase II Results for Sinusitis Drug CM512
Text size
Background

Keymed Biosciences Inc. (02162.HK) announced that its self-developed Class 1 new drug, CM512, met all study endpoints in a Phase II clinical trial for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP). The company reported positive topline results following the completion of data unblinding and preliminary statistical analysis.

Key Trial Findings

The study demonstrated that CM512 was effective and well-tolerated across all tested dosage groups. According to the company's announcement, the drug showed both rapid onset and durable efficacy.

Key outcomes from the Phase II trial include:

  • Rapid Efficacy: Patients experienced a reduction in nasal polyp size, significant improvement in nasal congestion, and restoration of smell function as early as the fourth week of treatment.
  • Durable Response: A single injection provided a therapeutic effect that was sustained for six months. The change in Nasal Polyp Score (NPS) from baseline at 24 weeks was significantly superior to the placebo group.
  • Safety Profile: CM512 exhibited a favorable safety and tolerability profile. The incidence of treatment-emergent adverse events (TEAEs) was comparable to the placebo group, and no serious adverse events were reported in the CM512 arms. The rate of anti-drug antibodies (ADA) was also noted as extremely low.

Path to Phase III

Sample IUX Markets – In-articleAd

Based on these positive Phase II results, Keymed Biosciences is preparing to initiate a Phase III clinical study for CM512 in the treatment of CRSwNP. The company has established the dosing regimen for the upcoming pivotal trial.

The selected treatment plan for the Phase III study will be 300mg administered once every 24 weeks (Q24W), or once every six months. Keymed stated that more detailed data from the Phase II trial will be published in international academic journals or presented at future academic conferences.

Drug Profile and Context

CM512 is an investigational bispecific antibody designed to target both thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13), two key cytokines involved in Type 2 inflammation, which is a primary driver of CRSwNP. The positive trial data positions CM512 as a potential long-acting treatment option for this chronic inflammatory condition, which could offer a significant convenience advantage for patients if approved.

Read next

More on Stocks
Back to latest news

LATEST